News &
Events
CORPORATE ANNOUNCEMENTS & PORTFOLIO UPDATES
Featured Article
Solaris has announced the launch of brivaracetam tablets, a generic version of UCB’s branded epilepsy medication Briviact.
The tablets are approved for managing partial-onset seizures in patients as young as 1 month old — a condition that impacts millions of people each year.
The generic is offered in five strengths — 10mg, 25mg, 50mg, 75mg, and 100mg — and comes in 60-count bottles.
This release marks a significant step for
Solaris Launches Generic Briviact
Solaris has announced the launch of brivaracetam tablets, a generic version of UCB’s branded epilepsy medication Briviact.
The tablets are
Solaris Pharma Receives FDA Approval for Tazarotene Gel, 0.05% and 0.1%
Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris Pharma Receives FDA Approval for First Generic Clindamycin Phosphate Topical Gel, 1%
BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) — Solaris Pharma Corporation (“Solaris” or the “Company”) announced today that the Company
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Once-A-Day)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Oil, 0.01% (Ear Drops)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated